Scarica l'app Stockscreener
6.08
0.98%
-0.05
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
VRCAVerrica Pharmaceuticals Inc Latest SEC Filings - Finviz
VRCA News | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell 3000E Growth Benchmark - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell 3000E Index - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell Microcap Index - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Number of shareholders of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Enterprise value to EBITDA forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Price to book forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Verrica Pharmaceuticals Inc. Cash Flow – DUS:1NE0 - TradingView
Price to sales forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Verrica Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VRCA) - TradingView
VRCA Forecast — Price Target — Prediction for 2027 - TradingView
Verrica Pharmaceuticals Inc. Actuals & Estimates (SWB:1NE0) - TradingView
1NE0 Forecast — Price Target — Prediction for 2027 - TradingView
A41A98 Forecast — Price Target — Prediction for 2027 - TradingView
Verrica Advances Wart Treatment Program With Phase 3 Trial Expansion - MyChesCo
Verrica Pharmaceuticals Inc (VRCA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
H.C. Wainwright reiterates Verrica stock rating on trial progress - Investing.com UK
Milestone Alert: First US Patient Dosed in the Second Phase 3 Trial of Verrica’s YCANTH for Common Warts - The Dermatology Digest
H.C. Wainwright reiterates Verrica stock rating on trial progress By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Verrica doses first U.S. patient in common warts trial By Investing.com - Investing.com South Africa
Verrica doses first U.S. patient in common warts trial - Investing.com
Verrica starts Phase 3 common-warts trial with first U.S. patient - Stock Titan
Verrica Pharmaceuticals Inc (VRCA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Institutional Confidence - TradingKey
Verrica Pharmaceuticals (VRCA) Holds Steady Near $6.0, Eyeing Resistance at $6.3Put Dominated - newsline.com
Verrica Pharmaceuticals Stockoperations and strategy in focus after YCANTH launch - Ad-hoc-news.de
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISI - GuruFocus
Verrica’s COVE-3 Wart Study Moves Forward, Offering a Small but Notable Catalyst for VRCA and VEEV - TipRanks
Verrica Pharmaceuticals (NASDAQ: VRCA) director awarded 16,000 stock options at $6.04 - Stock Titan
Director at Verrica (NASDAQ: VRCA) receives 16,000 stock options - Stock Titan
Verrica (VRCA) director Diem Nguyen awarded 16,000 stock options at $6.04 - Stock Titan
Verrica (VRCA) CMO receives 233,840 performance-vested stock options - Stock Titan
Verrica (VRCA) COO receives 171,340 stock options with price hurdles - Stock Titan
Verrica (VRCA) CEO awarded 512,269 options with $15 and $25 vesting hurdles - Stock Titan
Director Gavin Corcoran receives 16,000 Verrica (VRCA) stock options at $6.04 - Stock Titan
Verrica Pharmaceuticals (NASDAQ: VRCA) shareholders approve new equity plan and re-elect directors - Stock Titan
VRCA: YCANTH adoption accelerates, pipeline advances, and cash runway extends into 2027 - TradingView
Number of shareholders of Verrica Pharmaceuticals Inc. – LS:A41A98 - TradingView
Verrica Shares Drop With Jefferies Conference Ahead, Cash Warning Still in Focus - Bez Kabli
Verrica Stock Slips Before Jefferies as Cash Warning Shadows YCANTH Growth - Bez Kabli
VRCA Stock Price, Quote & Chart | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals to present at Jefferies Global Healthcare Conference June 4, 2026 - Pluang
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
VRCA Assumed by HC Wainwright & Co. -- Buy Rating Announced - GuruFocus
1.21%
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):